Experimental and computational analysis of biased agonism on full-length and a C-terminally truncated adenosine A2A receptor

Gemma Navarro a,b,1, Angel Gonzalez c,1, Stefano Campanacci d,1, Rafael Rivas-Santisteban a,d, Irene Reyes-Resina b,d,2, Nil Casajuana-Martin 1, Arnau Cordomí c, Leonardo Pardo c,1, Rafael Franco b,e,1,*

a Dept. Biochemistry and Physiology, Faculty of Pharmacy and Food Science. Universitat de Barcelona. Barcelona, Spain
b Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas. Instituto de Salud Carlos III, Madrid, Spain
c Laboratori de Medicina Computacional, Unitat de Bioestadística, Facultat de Medicina, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain d Faculty of Chemistry, Universitat de Barcelona, Barcelona, Spain
d Dept. Biochemistry and Molecular Biomedicine. School of Biology. Universitat de Barcelona. Barcelona, Spain
e School of Chemistry. Universitat de Barcelona. Barcelona, Spain

643, 08028 Barcelona, Spain.
burg 39118, Germany.

ABSTRACT

Biased agonism, the ability of agonists to differentially activate downstream signaling pathways by stabilizing specific receptor conformations, is a key issue for G protein-coupled receptor (GPCR) signaling. The C-terminal domain might influence this functional selectivity of GPCRs as it engages G proteins, GPCR kinases, β-arrestins, and several other proteins. Thus, the aim of this paper is to compare the agonist-dependent selectivity for intracellular pathways in a heterologous system expressing the full-length (A2AR) and a C-tail truncated (A2AR D40R) that is already targeted in Parkinson’s disease using a first-in-class drug. Experimental data such as ligand binding, cAMP production, β-arrestin recruitment, ERK1/2 phosphorylation and dynamic mass redistribution assays, which correspond to different aspects of signal transduction, were measured upon the action of structurally diverse compounds (the agonists adenosine, NECA, CGS-21680, PSB-0777 and LUF-5834 and the SCH-58261 antagonist) in cells expressing A2AR and A2AR D40R. The results show that taking cAMP levels and the endogenous adenosine agonist as references, the main difference in bias was obtained with PSB-0777 and LUF-5834. The C-terminus is dispensable for both G-protein and β-arrestin recruitment and also for MAPK activation. Unrestrained molecular dynamics simulations, at the μs timescale, were used to understand the structural arrangements of the binding cavity, triggered by these chemically different agonists, facilitating G protein binding with different efficacy.

© 2020 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Adenosine triphosphate (ATP) is the main energy-transfer molecule and adenosine is one of its main metabolites. Adenosine receptors appeared early in evolution, as sensors of ATP decay, because excess of adenosine correlates with ATP depletion. They are considered as the most ancient within the class A (or rhodopsin-like) G-protein-coupled receptor (GPCR) family. Moreover, phylogenetic studies suggest that adenosine receptors were the first to start diverging [1] from the MECA receptor cluster [2], which is formed by the melanocortin, endothelial differentiation sphingolipid, and cannabinoid receptors. There are four identified mammalian adenosine receptors (humans included) whose cognate heterotrimeric G proteins are Gia (A1 and A3) or Gs/Golf (A2A and A2B) [3].

The crystal structure of the A2A receptor (A2AR) was the first reported for the G-protein-coupled receptor (GPCR) family [4]. Today, there are nearly fifty structures of A1R and A2B that show agonists, antagonists, and/or to G proteins [5]; all of them displaying the common features of class A GPCRs [6]. Unfortunately, the N- and C-terminal domains, which are highly variable in sequence, length, and structure [7], have been removed for crystalization purposes. The long C-terminal domain of A2AR (about 122 amino acids) is known to engage G proteins, GPCR kinases, arrest-
ins and several other proteins [8,9]. The C-terminus is also responsible for the constitutive activity of the receptor [10], influences the quaternary structure of heteromers [11,12], and is involved in differential intracellular signaling [13].

A2AR offers numerous possibilities for therapeutic applications [14–16]. A2AR antagonists show promise, among others, in Alzheimer’s and Parkinson’s diseases, attention-deficit hyperactivity disorder, depression, and anxiety. Istradefylline, one of the most studied antagonists, is safe and efficacious in Parkinson and was approved in Japan as Nourista™ and by the US Food and Drug Administration as Nouriant™ [17]. A2AR agonists could be used in Niemann Pick type C disease, autism-spectrum disorders, and schizophrenia. Regadenoson, a selective A2AR agonists that is a coronary vasodilator, was approved in the United States as Lexiscan™.

These facts open the possibilities for more drug approvals, both agonists and antagonists, related to adenosine receptors. Thus, the aim of this work was double. First, we wanted to analyze the agonist-dependent selectivity for intracellular pathways, known as functional selectivity or biased agonism, using structurally diverse compounds in a heterologous system expressing A2AR. Biased agonists might offer attractive therapeutic properties relative to their unbiased counterpart, circumstance that remains to be validated in clinical trials [18]. In fact, adenosine receptor biased agonists could be used for cardioprotection without bradycardia as a serious adverse effect [19,20]. Second, we analyzed in living cells the effect of the C-terminal domain of A2AR in ligand binding and in agonist-induced signaling.

2. Materials and methods

2.1. Reagents

Adenosine, NECA, CGS-21680, PSB-0777, LUF-5834 and SCH-58261 were purchased from Tocris Biosciences (Bristol, UK). HEPES was purchased from SigmaAldrich (St. Louis, MO, US). Stock solutions were prepared in DMSO. Aliquots of these stock solutions were kept frozen at −20 °C until use.

2.2. Human embryonic kidney 293T (HEK-293T) cells

Human embryonic kidney 293T (HEK-293T) cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco, Paisley, Scotland, UK) supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 100 units/ml penicillin/streptomycin, MEM non-essential amino acids solution (1/100) and 5% (v/v) heat inactivated fetal bovine serum (FBS) [all supplements were from Invitrogen, (Paisley, Scotland, UK)]. Cells were incubated in a humid atmosphere of 5% CO2 at 37 °C. 24 h after seeding in 6-well or 96-well (for ERK phosphorylation assay) plates, cells were transiently transfected with cDNA coding for wild-type A2AR or A2ARΔ96 (amino acids 372–412 on the C-terminal domain were deleted [21]) with the plasmid (PolyEthylhyleneImine, SigmaAldrich) method as previously described [13,22]. Truncation of this part of the C-tail does not remove the proposed phosphorylation codes (PxPxxP/E or PxxPxxP/E/D, where P represents phospho-serine or phospho-threonine) for arrestin recruitment [23]. This phosphorylation code starts 33 amino acids after P7.50 of the NPxP motif in human rhodopsin, whereas truncation of A2AR starts 87 amino acids after P7.50. Cells were incubated for 4 to 5 h with the cDNA of interest, PEI and NaCl in serum-free medium. After that, the serum-free medium was replaced by complete culture medium and cells were incubated for 48 h at 37 °C in 5% CO2 humid atmosphere. The sequences in the plasmids were those coding for human receptors. It should be noted that within a given experimental session, for instance of determination of cAMP levels, all agonists (plus/minus antagonist when indicated) were tested in the same batch of transfected cells.

2.3. Homogeneous HTRF binding assays

HEK-293T cells growing in 6-well plates were transiently transfected with 1 μg of plasmid encoding for pHALO-tagged human A2AR (pHALO-A2AR, Cisbio Bioassays, Codolet, France) or 1 μg of plasmid encoding for pHALO-tagged human A2ARΔ96 and incubated at 37 °C in a 5% CO2 humid atmosphere (24 h).

2.4. Covalent labeling of cells expressing pHALO-tagged receptors

48 h post transfection culture medium was removed, cells were washed with PBS and incubated with 100 nM of HALO-Lumi4Tb, a terbium derivative of 6-benzylguanine (SSNPTBC, Cisbio Biosays, Codolet, France) - previously diluted in TagLite Buffer (TLB) (LABMED, Cisbio Biosays, Codolet, France) for 1 h at 37 °C under 5% CO2 humid atmosphere. After that, cells were washed with PBS to remove the excess of HALO-Lumi4Tb, detached with Versene (Gibco Life Technologies, Paisley, Scotland, UK), centrifuged at 1,500 rpm for 5 min and resuspended in TLB. Densities of 10,000 cells/well were used to carry out binding assays in white opaque 384-well plates.

2.5. Non-radioactive homogeneous time-resolved FRET-based binding assays

Saturation binding experiments were performed by incubating cells expressing Tb-labeled HALO-A2AR with increasing concentrations of the A2AR antagonist SCH-442416, conjugated to a fluorescent probe developed by Cisbio (red A2AR ligand, purchased from Cisbio Biosays, Codolet, France). The unspecific signal was obtained by incubating cells expressing Tb-labeled HALO-A2AR with increasing concentrations of red A2AR ligand in the presence of 10 μM unlabeled SCH-58261. Both, fluorescent ligands and unlabeled compounds, were diluted in TLB. 10 μl of labeled cells (10,000 cells/well) were loaded onto 384-well white plates and 5 μl unlabeled SCH-58261 (10 μM final concentration) or TLB were added, followed by the addition of 5 μl of increasing concentrations (0–60 nM range) of red A2AR ligand. Plates were incubated protected from light for 2 h at room temperature before time-resolved fluorescence resonance energy transfer (TR-FRET) signal reading. The specific binding was calculated by subtracting the unspecific binding from the total binding.

For competition binding assays, HEK-293T cells transiently expressing Tb-labeled HALO-A2AR or A2ARΔ96 were incubated with 20 nM fluorophore-conjugated A2AR ligand, in the presence of increasing concentrations (0–10 μM range) of agonists (or antagonists when indicated). Plates contained 10 μl of labeled cells, and 5 μl of tested compounds or TLB were added prior to the addition of 5 μl of the red A2AR ligand. Plates were then incubated for at least 2 h at room temperature prior to TR-FRET signal detection. Detailed description of the HTRF assay is found elsewhere [24].

2.6. Signal detection and data analysis

Signal was detected using a PHERAnStar FS (BMG Lab technologies, Offenburg, Germany) microplate reader equipped with a FRET optoelectric module allowing donor excitation at 337 nm and signal collection at both 665 and 620 nm. A frequency of 10 flashes/second was selected for the xenon flash lamp excitation. The signal was collected at both 665 and 620 nm using the following time-resolved settings: delay, 150 ms; integration time, 500 ms. HTRF ratios were obtained by dividing the acceptor signal (665 nm) by the donor sig-
nal (620 nm) and multiplying this value by 10,000. The 10,000- multiplying factor is used solely for the purpose of easier data handling.

Data were analyzed using Prism 7 software (GraphPad Software, Inc., San Diego, CA), and competition data were fitted by non-linear regression to a one site-fit logIC_{50} competition curves were -in all cases- monophasic. K_{D} (dissociation constant) values of the fluorescent ligand were obtained from the specific binding saturation curves. Note that B_{max} values obtained from HTRF saturation curves do not reflect absolute values of receptor binding sites. K_{D} values were determined from competition binding assays by using the calculated IC_{50} and K_{D} values and the Cheng-Prusoff equation [25].

2.7. cAMP determination

HEK-293T cells were grown in 6-well plates and transiently transfected with cDNAs for A_{2A}R or for A_{2A}^{40R} as described in 2.2. Two hours before initiating the experiment, medium was replaced by serum-free DMEM medium. Then cells were detached, isolated by centrifugation (5 min at 1,500 rpm) and resuspended in DMEM containing 50 μM zardaverine (phosphodiesterase inhibitor) to prevent degradation of cAMP, and 5 mM HEPES (pH 7.4). Cells were placed in white 384-well plates (PerkinElmer) (6,000 cells/well) and incubated with antagonists or vehicle for 15 min before treatment with agonist or vehicle for 15 min. Finally, cAMP-Eu and the fluorescent antibody were added. Readings were performed after one hour incubation at 25 °C. Homogeneous time-resolved fluorescence energy transfer (HTRF) measures were performed using the Lance Ultra cAMP kit (PerkinElmer, Waltham, MA, US). Fluorescence at 665 nm was measured in a PHERAstar Flagship plate reader equipped with an HTRF optical module (BMG Labtechnologies, Offenburg, Germany).

2.8. ERK1/2 phosphorylation assays

HEK-293T cells were grown on transparent Biocat Poly-D-Lysine 96-well plates (Deltalab) and kept at the incubator for 24 h. Then cells were transiently transfected with cDNA coding for A_{2A}R or A_{2A}^{40R} and incubated for 48 h at 37 °C in a 5% CO_{2} humid atmosphere. Supplementary Fig. S1A shows that treatment with CGS-21680 in non-transfected HEK-293T cells is not significantly different to the basal condition. Thus, the expression level of A 2AR in non-transfected HEK-293T cells is negligible. 2 h before initiating the experiment, medium was substituted by serum-free DMEM. Cells were stimulated at 25 °C for 10 min with vehicle or agonists (Supplementary Fig. S1D). ERK phosphorylation was measured at “short” times to detect G-protein mediated signal. After that, cells were washed twice with cold PBS before the addition of lysis buffer (30 μl/well; Perkin Elmer, Waltham, MA, US) and incubated for 15 min at 25 °C on a Heidolph Titramax 100 shaker. 10 μl of each cell lysate was transferred to white ProxiPlate 384-well microplates (PerkinElmer, Waltham, MA, USA). ERK1/2 phosphorylation was determined using AlphaScreen®SureFire® kit (Perkin Elmer, Waltham, MA, US): 5 μl/well of acceptor beads were added. Plates, protected from light, were incubated for 2 h at 25 °C. Finally, 5 μl/well of donor beads were added and plates, protected from light, were incubated for 2 h before analysis. Fluorescence was determined using an EnSpire® Multimode Plate Reader (PerkinElmer, Waltham, MA, USA). The value of reference (100%) was that achieved in the absence of any treatment (basal). The effect of ligands was given in percentage respect to the basal value.

2.9. β-Arrestin 2 recruitment

HEK-293T cells were transiently transfected with 0.625 μg of cDNA coding for β-arrestin 2-Rluc and 2 μg of cDNA coding for A_{2A}^{40R}-YFP or with 1.5 μg of cDNA coding for β-arrestin 2-Rluc and 4 μg of cDNA coding for A_{2A}^{40R}-YFP. BRET experiments were performed 48 h after transfection. Cells were detached using HBSS containing 0.1% glucose, centrifuged for 5 min at 3,200 rpm and resuspended in the same buffer. Protein concentration was quantified by using the Bradford assay kit (Bio-Rad, Munich, Germany). Hereafter, YFP fluorescence at 530 nm was quantified in a FluorStar Optima Fluorimeter (BMG Labtechnologies, Offenburg, Germany) to quantify receptor-YFP expression. To measure β-arrestin recruitment, cells (20 μg of protein) were distributed in 96-well microplates (Corning 3600, white plates with white bottom) and were incubated for 10 min with antagonists. Cells were then stimulated with agonists prior to the addition of 5 μM Coelenterazine H (Molecular Probes, Eugene, OR). BRET between β-arrestin 2-Rluc and receptor-YFP was determined and quantified at 5 min after adding coelenterazine H. This time of response was selected from time-response curves (Supplementary Fig. S1C). The readings were collected using a Mithras LB 940 (Berthold Technologies, Bad Wildbad, GE), which allows the integration of the signals detected in the short-wavelength filter (485 nm) and the long wavelength filter (530 nm). To quantify protein-YFP expression, luminescence readings were also collected 10 min after the addition of 5 μM coelenterazine H.

2.10. Dynamic mass redistribution assays (DMR)

Cell mass redistribution induced upon receptor activation was detected by illuminating with polychromatic light the underside of a biosensor and measuring the changes in the wavelength of the reflected monochromatic light, that is a sensitive function of the index of refraction. The magnitude of the wavelength shift (in picometers) is directly proportional to the amount of mass redistribution. 48 h before the assay, HEK-293T cells were transiently transfected with 2 μg of cDNA coding for A_{2A}R or A_{2A}^{40R}. HEK-293T cells were seeded in 384-well sensor microplates to obtain 70–80% confluent monolayers constituted by approximately 10,000 cells/well. Prior to the assay, cells were washed twice with assay buffer (HBSS with 20 mM HEPES, pH 7.15 and 1% BSA) (Sigma-Aldrich, St. Louis, MO, US) and incubated for 2 h with assay-buffer containing 0.1% DMSO (24 °C, 30 μl/well). Hereafter, the sensor plate was scanned, and a baseline optical signature was recorded for 10 min before adding 10 μl of the selective antagonists for 30 min, followed by the addition of 10 μl of the selective agonists; all test compounds were diluted in assay buffer. Then, DMR responses were monitored for at least 5000 s in an EnSpire® Multimode Plate Reader (PerkinElmer, Waltham, MA, USA) by a label-free technology. Results were analyzed using EnSpire Workstation Software v 4.10.

2.11. Calculation of bias factor

Bias factor (bias) was calculated with the following formulas adapted from [26] in which t represents the agonist efficacy, and K_{A} the agonist affinity [27].

\[
\log \text{bias} = \Delta \log \left( \frac{\tau}{K_A} \right)_h - \Delta \log \left( \frac{\tau}{K_A} \right)_b
\]

\[
bias = 10^{\Delta \log \left( \frac{\tau}{K_A} \right)_h} - \frac{1}{10^{\Delta \log \left( \frac{\tau}{K_A} \right)_b}}
\]
log (τ/Kₐ) is defined as the transduction coefficient or synergistically as logR, a parameter that can be used to compare agonist activity between different systems. The transduction coefficient is a measure of the ability of a ligand to activate the receptor [28].

The pathway of reference j₁ was cAMP-dependent Gs-coupling, whereas the other pathways (ERK1/2 phosphorylation, β-arrestin 2 recruitment, or DMR) were j₂. τ denotes the maximum value in each response and Kₐ is the antilogarithm of half maximal effective concentration (EC₅₀ if the agonist provides an increase response, IC₅₀ if the agonist provides a reduction of the response induced by another reagent).

2.12. Computational methods

Preparation of protein structure and ligand parametrization. Crystal structures of the A₂AR in its active intermediate state in complex with the adenosine (PDB id 2YDO), NECA (2YDV) and CGS-21680 (4UHR) agonists, and the crystal structure of A₂AR in its inactive state in complex with the ZM241385 antagonist (PDB id 4EII) were obtained from the Protein Data Bank (rcsb.org). Fusion proteins were removed and stabilizing mutations were mutated to the native sequence using MODELLER v9.12 [29]. Parameters for adenosine, NECA, CGS-21680, PSB-0777, LUF-5834 and SCH-58261 were obtained from the general Amber force field (GAFF) and HF/6-31G*/HF/6-31G*'-derived RESP atomic charges calculated with Gaussian09.

Molecular docking. The PSB-0777 and LUF-5834 agonists were docked into the active intermediate state (2YDV) and the SCH-58261 antagonist was docked into the inactive state (4EII) using the Molecular Operating Environment (MOE) software (Chemical Computing Group Inc., Montreal, Quebec, Canada). One hundred docking solutions per ligand were generated by the triangle matcher algorithm into the active site of the receptor structures. Top-ranking solutions were inspected and conformations in which the central moiety of PSB-0777 and the aminopyridine group of LUF-5834 were located in the same region as the adenine moiety of adenosine and NECA were selected (Supplementary Fig. S2). The binding pose of SCH-58261 was selected in such a manner that the orientation of its pyrazolo-triazolo-pyrimidine central moiety was similar to the bicyclic triazolotrazine core of the highly potent selective antagonist ZM241385 found in the 4EII structure (Supplementary Fig. S2).

Molecular dynamics (MD) simulations. The complexes of adenosine, NECA, CGS-21680, PSB-0777 and LUF-5834 with the intermediate active state of A₂AR and the complex of SCH-58261 with the inactive structure of A₂AR (see above) were embedded in a pre-equilibrated lipid bilayer box containing 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine (POPC), water molecules (TIP3P) and monoatomic Na⁺ and Cl⁻ ions (0.2 M). Assignment of ionization states and hydrogens at physiological pH for the selected structures was conducted with the Protonate3D method [30] as implemented in MOE. D2.50 was deprotonated (negatively charged) for antagonist-bound receptor simulations and protonated (neutral) for agonist-bound receptor simulations [31], whereas H264 was protonated (positively charged) in all simulations [32]. A sodium ion was placed, near the negatively charged D2.50, in the inactive, antagonist-bound, structure of A₂AR [33,34]. Molecular systems were subject to a 1000 cycles of energy minimization, followed by 20 ns of gradual relaxation of positional restraints (corresponding to 100, 50, 25 and 10 kJ.mol⁻¹ nm⁻²) at protein backbone coordinates before the production phase in order to hydrate the receptor cavities and allow lipids to pack around the protein. After equilibration, unrestrained MD simulation (3 replicas of 1 μs giving a total of 3 μs of sampling time) were produced for each ligand-receptor complex at a constant temperature of 300 K using separate v-rescale thermostats for the receptor, ligands, lipids and solvent molecules. A time step of 2.0 fs was used for the integration of equations of motions. All bonds and angles were kept frozen using the LINCS algorithms. Lennard-Jones interactions were computed using a cutoff of 10 Å, and the electrostatic interactions were treated using PME with the same real-space cutoff under periodic boundary conditions. MD simulations were performed using GROMACS v5.0.7. The AMBER99SB force field as implemented in GROMACS, Berger parameters for POPC lipids, and the GAFF parameters for the ligands (see above) were used for the MD simulations, attending the performance of this protocol on membrane-protein systems [35].

2.13. Statistical analysis

Experimental data was managed and analysed with GraphPad Prism software version 7 (San Diego, CA, USA) or IBM SPSS Statistics version 25.0 (IBM Corp., NY, USA). Unless otherwise stated data are the mean ± S.E.M (n = 5 or higher). P-values lower than 0.05 were considered statistically significant.

3. Results and discussion

3.1. Ligand binding experiments

We studied the binding of the agonists adenosine, NECA and CGS-21680, the partial agonists PSB-0777 and LUF-5834, and the selective antagonist SCH-58261 by homogeneous time-resolved fluorescence (HTRF) experiments, schematized in Fig. 1A, in living HEK-293T cells expressing either wild type (wt) A₂AR or a truncated receptor (A₂Δ40R, lacking the last 40 amino acids of the C-terminal end) tagged with HaloTag on the N-terminus (see 2.3–2.5). First, a saturation curve was performed using a fluorescence-conjugated antagonist (Fig. 1B). The obtained Kᵣ values were 1.7 nM and 1.2 nM for full-length A₂AR and A₂Δ40R, respectively (Table 1). Subsequently, competition assays were performed using 20 nM of the fluorescence-conjugated antagonist and increasing amounts of the ligands (Fig. 1C-1D). The Kᵣ value of each compound was calculated from Kᵣ and Kᵣ values using the Cheng-Prusoff expression [25] (Table 1). The obtained Kᵣ values are in the range of those obtained in radioligand binding assays for isolated membranes from tissues or transfected cells. According to this assay, the Kᵣ values of agonists are in the 13–219 nM range, LUF-5834 being the compound that binds A₂AR the strongest and PSB-0777 the weakest. Clearly, removal of the C-terminal domain results in weaker agonist binding to the orthosteric site (a ratio of Kᵣ values in the 1.4–4.4 range, which correspond to binding free energy differences between 0.2 and 0.9 Kcal/mol). On the other hand, removal of the C-terminal domain has a significant impact on the binding of the antagonist SCH-58261 (0.7 nM vs 113.9 nM for full-length A₂AR and A₂Δ40R, respectively; binding free energy difference of 3.0 Kcal/mol).

3.2. Molecular models of agonist binding

The binding of these compounds to A₂AR has been extensively studied by site-directed mutagenesis, computer simulations, and supported by the recent crystallographic data of adenosine, NECA and CGS in complex with A₂AR (reviewed in [36]). PSB-0777 and LUF-5834 were docked (see 2.12) using, as template, ligands solved in crystal structures with homologous chemical scaffolds (see Supplementary Fig. S2). All molecules but LUF-5834 are structurally related through a common adenosine core. Fig. 2 summarizes the binding modes of all compounds, emphasizing common/different areas of the receptor occupied by each ligand. In order to understand the molecular mechanism of receptor activation (see 3.5),
we studied by molecular dynamics (MD) simulations (see 2.12) the interactions of crucial ligand moieties to key receptor amino acids in all these regions. Detailed analysis of the simulations shows that these binding modes were stable during the unbiased 1 sM MD simulations (three replicas) as shown by the relatively low movement in root mean-square deviation (rmsd) plots of the receptor and ligand heavy atoms, as well as the conservation of the secondary structure elements of A₂AR (Supplementary Figs. S3-S5).

As shown in Fig. 2, three regions (blue, green and yellow rectangles) are invariably occupied by functional groups of all the studied compounds, illustrated by the binding of adenosine in the central panel. The heterocyclic site (blue rectangle) corresponds to the central region and accommodates the adenine moiety of adenosine, NECA, CGS-21680, and PSB-0777, and the aminopyridine group of LUF-5834 through aromatic/hydrophobic interactions with F168, M5.38, M7.35, I7.39 (numbering in Ballesteros and Weinstein scheme [37], except for residues outside helices in which sequence numbers are used) and polar interactions of the exocyclic nitrogen with N6.55 (Supplementary Fig. S3). The second region (green rectangle) accommodates the 5₀-hydroxymethyl (adenosine and PSB-0777), N-ethylcarboxamido (NECA and CGS-21680) and hydroxyphenyl group of LUF-5834 (Fig. 2). The 5₀-hydroxymethyl group attached to the ribose ring of adenosine and PSB-0777 and the hydroxyphenyl group of LUF-5834 hydrogen bond H6.52 during all the simulation time (Supplementary Fig. S3). NECA and CGS-21680 replace the 5₀-hydroxymethyl group by the longer N-ethylcarboxamido group that can directly interact with both H6.52 and T3.36 (Supplementary Fig. S3). Several X-ray structures of A₂AR contain crystallized water molecules in the environment of T3.36 and N5.42 [4] that are important for the activity of GPCRs [38,39]. Supplementary Fig. S6 shows that during the MD simulations adenosine, PSB-0777 and LUF-5834 maintain this water bridge, whereas NECA and CGS-21680 cannot because the N-ethylcarboxamido group interacts with T3.36. Finally, the third region (yellow rectangle) is occupied by the ribose moiety of adenosine derivatives and by the carbonitrile substituent of LUF-5834. Most important interactions in this site imply the formation of...
hydrogen bonds from the hydroxyl groups at positions C2 and C3 of the ribose moiety of adenosine derivatives with the S7.42 and H7.43 residues.

Three additional regions are occupied by the ligands (orange, cyan and black in Fig. 2). The ethyl group of the N-ethylcarboxamido moiety of NECA and CGS-21680 extends deep into the binding pocket (orange), forming hydrophobic interactions with C5.46 (Supplementary Fig. S3). These interactions between aliphatic chains and sulfur-containing amino acids have been shown to be of high energy [40]. The long substituents of CGS-21680 and PSB-0777 expand toward the extracellular loops was specific for all agonists as shown by the blockade of cAMP production using the selective receptor antagonist SCH-58261 (Supplementary Fig. S8).

3.3. Agonist-induced signaling responses

Next, we measured four functional read-outs that correspond to different steps of the signaling pathways in cells expressing full-length A2AR or A2A40R: cAMP production, β-arrestin recruitment, ERK1/2 phosphorylation, and dynamic mass redistribution (DMR) assays (Fig. 3 and Table 2). Immediately following receptor activation, cAMP levels increase as the result of adenylyl cyclase activation by Gs. Next, receptor phosphorylation by G protein kinases triggers β-arrestin recruitment. Later, ERK signaling is regulated by G protein αi/and β-arrestin. DMR accounts for events that occur much later in the signaling pathway such as protein trafficking, rearrangement of cytoskeleton and adhesion or morphological changes. The amount of transfected cDNA for A2AR and A2A40R was adjusted to obtain similar receptor expression levels (Supplementary Figs. S1C-S1D). In our cAMP assay conditions, adenosine, NECA, and CGS-21680 behaved as full agonists, whereas PSB-0777 and LUF-5834 were partial agonists on full-length A2AR. The effect was specific for all agonists as shown by the blockade of cAMP production using the selective receptor antagonist SCH-58261 (Supplementary Fig. S8). β-arrestin recruitment assays showed that PSB-0777 and NECA are more efficient in recruitment than adenosine and CGS-21680. Remarkably, LUF-5834, which is a partial agonist in the cAMP assay, is as efficient as CGS-21680 and adenosine in β-arrestin recruitment. pERK1/2 dose–response curves follow similar patterns as cAMP curves, with the exceptions of PSB-0777 in β-arrestin recruitment. pERK1/2 dose–response curves show a right-shift of the cAMP dose–response curves (a ratio of EC50 values in the 2.2–9.8 range, similar to the range of Ki ratios) with almost no change in Emax for all agonists, with the exception of LUF-5834 whose effect became almost negligible in the truncated form of the receptor (Fig. 3 and Table 2). C-terminal truncation provides a small decrease in β-arrestin recruitment with no changes in Emax rank order relative to full-length A2AR. pERK1/2 dose–response curves of A2A40R were very similar to full-length A2AR except that pEC50 increased for the truncated receptor, which goes against the general trend, and the potency of NECA and PSB-0777 became close to that of adenosine and CGS-21680. Finally, DMR read-outs of A2A40R were almost negligible for NECA and adenosine while we could observe a higher signal for PSB-0777 compared to that of the other compounds in A2AR and A2A40R.
nal, i.e. cAMP response elicited by adenosine (see 2.8). Bias factors for CGS-21680, PSB-0777, LUF-5834 and NECA agonists in cAMP, β-arrestin recruitment, ERK1/2 phosphorylation and DMR signaling responses are summarized in the radar plot of Fig. 4. Adenosine and CGS-21680 are balanced agonists with similar bias factors for the four pathways, whereas NECA has small factors for DMR and β-arrestin recruitment and LUF-5834 has small factors for all responses other than cAMP. By contrast, PSB-0777 has a higher bias for the pERK1/2 response. Truncation of the C-terminus makes LUF-5834 and PSB-0777 more balanced. In fact, LUF-5834 acquires the largest bias factors for β-arrestin recruitment, ERK1/2 phosphorylation and DMR. By contrast, NECA keeps the small factors for β-arrestin recruitment and DMR. Overall the results are consistent with the C-terminus being dispensable for both G-protein and arrestin recruitment and also for MAPK activation (ERK1/2 phosphorylation and DMR), with only minor differences in signaling compared to full-length A2AR.

3.5. Molecular mechanisms of agonist-induced receptor activation

The first step to understand the mechanisms of agonist-induced receptor activation, was to compare by MD simulations the trajectories of amino acids at positions 3.40, 5.50, and 6.44 (Fig. 5), which have been named as the “P-I-F” motif [44], the “transmission switch” [45], the “triad core” [46] or the connector region [6], in the presence of the agonists adenosine, NECA, CGS-21680, PSB-0777 and LUF-5834 and the antagonist SCH-58261. These residues, located below the ligand binding cavity and above the G protein or arrestin binding cavity (see Fig. 2), adopt different positions upon ligand binding. phosphorylation and DMR. Overall the results are consistent with the C-terminus being dispensable for both G-protein and arrestin recruitment and also for MAPK activation (ERK1/2 phosphorylation and DMR), with only minor differences in signaling compared to full-length A2AR.

3.4. Addressing biased agonism

Bias factors were calculated taking as reference the effect of adenosine, the endogenous compound, and the Gs-mediated signaling. cAMP response elicited by adenosine (see 2.8). Bias factors for CGS-21680, PSB-0777, LUF-5834 and NECA agonists in cAMP, β-arrestin recruitment, ERK1/2 phosphorylation and DMR signaling responses are summarized in the radar plot of Fig. 4. Adenosine and CGS-21680 are balanced agonists with similar bias factors for the four pathways, whereas NECA has small factors for DMR and β-arrestin recruitment and LUF-5834 has small factors for all responses other than cAMP. By contrast, PSB-0777 has a higher bias for the pERK1/2 response. Truncation of the C-terminus makes LUF-5834 and PSB-0777 more balanced. In fact, LUF-5834 acquires the largest bias factors for β-arrestin recruitment, ERK1/2 phosphorylation and DMR. By contrast, NECA keeps the small factors for β-arrestin recruitment and DMR. Overall the results are consistent with the C-terminus being dispensable for both G-protein and arrestin recruitment and also for MAPK activation (ERK1/2 phosphorylation and DMR), with only minor differences in signaling compared to full-length A2AR.

Table 2

| Pathway | cAMP assays | pEC50 | Emax | pEC50 | Emax | pEC50 | Emax | pEC50 | Emax | pEC50 | Emax | Emax |
|---------|-------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| A2AR    |             |       |       |       |       |       |       |       |       |       |       |       |
| PSB-0777|             |       |       |       |       |       |       |       |       |       |       |       |
| LUF-5834|             |       |       |       |       |       |       |       |       |       |       |       |
| Adenosine|             | 8.0   | 156.6 | 8.1   | 163.5 | 7.8   | 21.4  | 7.7   | 23.7  | 7.5   | 373.0 | 7.7   | 326.9 |
| PSB-0777|             | 9.0   | 156.6 | 9.0   | 166.0 | 7.9   | 34.9  | 7.8   | 31.3  | 8.3   | 392.1 | 8.2   | 302.6 |
| LUF-5834|             | 8.0   | 155.1 | 8.2   | 163.4 | 7.9   | 25.9  | 7.8   | 26.8  | 7.4   | 373.5 | 7.7   | 315.2 |

Fig. 3. Signaling in cells expressing either A2AR or A2ARΔ40. Dose response curves on 0.5 µM forskolin-induced cAMP levels, on β-arrestin recruitment, on ERK1/2 phosphorylation, and on dynamic mass redistribution (DMR). Data (n = 12, each in triplicates) for cAMP are given in percentage (100% represents the forskolin effect). Data (n = 10, each in triplicates) for BRET assays, used to determine phosphorylation, and on dynamic mass redistribution (DMR). Data (n = 12, each in triplicates) for cAMP are given in percentage (100% represents the forskolin effect). Data (n = 10, each in triplicates) for BRET assays, used to determine phosphorylation, and on dynamic mass redistribution (DMR).
between the centroid (calculated from 100 snapshots obtained during 1 μs of unbiased MD simulations) of A2AR bound to agonists and the centroid of A2AR bound to the antagonist. No deviations from normality (Shapiro-Wilk test) are observed in all variables, thus, correlation analyses were performed using a Pearson test for continuous, normally distributed variables.

Although ligand efficacy is a function of multiple factors, we found a clear statistically significant correlation between $E_{\text{max}}$ in cAMP assays and the movement of the side chains of T3.36 ($p = 0.033$) and W6.48 ($p = 0.015$) above the “transmission switch” and Y5.58 ($p = 0.039$) below the “transmission switch” (Supplementary Table S1). Y5.58 is a key amino acid in the process of receptor activation as it stabilizes the extended conformation of R3.50 in the active state [52]. Positions 3.36 and 6.48 have been described as conformational toggle or trigger switches involved in the initial agonist-induced receptor activation in other GPCRs such as cannabinoid CB1R [53,54], serotonin 5HT4R [55], melanocortin MC4R [56], mGlu2R [57], or A2AR [58]. With the aim of understanding at the molecular level the different activation trends among agonists, we explored the amount of time, in the MD simulations, the side chains of T3.36 and W6.48 spend in the gauche...
+ (g+/χ1 = 60°), gauche- (g-, χ1 = 180°) or trans (t, χ1 = 0°) conformations (see Supplementary Fig. S9). Clearly, the antagonist-bound structure favors the g+/g+ conformations of T3.36 and W6.48, whereas full agonists adenosine, NECA, and CGS-21680 favor the g-/g+ conformations. Notably, partial agonists PSB-0777 and LUF-5834 cannot achieve these g-/g+ conformations as frequently as full agonists. In this respect, it should be noted that Thr residues in this g- conformation are capable of hydrogen bonding the backbone carbonyl in the previous turn of the helix, which is known to trigger a local opening of the helix [59] that might be necessary for receptor activation. Importantly, the T3.36A mutation impedes signaling [43,60] and the W6.48A mutation has significant deleterious effects on receptor function [43].

In the case of $E_{\text{max}}$ in $\beta$-arrestin recruitment, we found a statistically significant correlation only with the movement of the side chain of E1.39 (p = 0.014) above the “transmission switch” (Supplementary Table S1). Because E1.39 and H7.43 might form an ionic interaction we calculated the distance between these side chains in the presence of the different agonists. However, we have not observed a statistically significant correlation between this distance and $E_{\text{max}}$ in $\beta$-arrestin recruitment.

4. Conclusion

The agonist-dependent selectivity for intracellular pathways of A2A R has been studied using, in synergy, molecular modeling tools and pharmacological assays. This combination of expertise has permitted to understand the structural arrangements of the binding cavity, triggered by chemically different agonists, facilitating G protein binding with different efficacy. The mechanism of agonist-induced $\beta$-arrestin recruitment seems more difficult to rationalize. First, different ligands stimulation might induce distinct patterns of receptor phosphorylation, which direct specific $\beta$-arrestin conformations and functional outcomes [61–63]. Second, there is increasing evidence that biased signaling could also be a consequence of binding kinetics [54–66]. In particular, a relationship between residence time of ligands with biased signaling in both A1R and A2A R [67,68] that is governed by a salt bridge between E169GCL2 and H264ECL1 in A2A R (Fig. 5A) [69,70] has been shown. Finally, the last 40 amino acids of the C-terminal end of A2A R receptor are dispensable for both G-protein and arrestin recruitment and also for MAPK activation (ERK1/2 phosphorylation and DMR).

5. Notes

Authors declare no conflict of interest.

Funding

This work was partially supported by grants from the Spanish Ministry of Economy and Competitiveness (BFU2015-64405-R, SAF2017-84117-R, RTI2018-094204-B-I00 and PID2019-109240RB-I00; they may include FEDER funds), the Alzheimer’s Association (AARDP-17-503612) and by a grant from Fundació la Marató de TV3 (201413-30).

CRediT authorship contribution statement

Gemma Navarro: Conceptualization, Validation, Supervision. Leonardo Pardo: Conceptualization, Validation, Project administration, Resources, Writing - original draft, Funding acquisition. Angel Gonzalez: Validation, Supervision, Project administration, Resources. Stefano Campanacci: Investigation. Rafael Rivas-Santisteban: Investigation. Irene Reyes-Resina: Investigation. Nil Casajuana-Martin: Investigation. Arnaud Cor

domi: Investigation, Validation, Supervision. References

[1] Mickael ME, Rajput A, Steny J, Wiersenslage L, Burglin T. An optimised phylogenetic method sheds more light on the main branching events of rhodopsin-like superfamilies. Comp Biochem Physiol Part D Genomics Proteomics 2016;20:85–94.
[2] Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB. The g-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 2003;63:1256–72.
[3] Fredholm BB, Izberman AP, Jacobson KA, Lindén J, Muller CE. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors—an update. Pharmacol Rev 2011;63:1–34.
[4] Jaakola VP, Griffith MT, Hansa MA, Cherevez V, Chien EY, Lane JR, et al. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an agonist. Science 2008;322:1211–7.
[5] Pandey-Szekeris G, Munk C, Tsonkov TM, Mordalski S, Harpsoe K, Hauser AS, et al. GPCRdb in 2018: adding GPCR structure models and ligands. Nucleic Acids Res 2018;46:D440–6.
[6] Weis W, Kohlkopf BK. The molecular basis of G protein-coupled receptor activation. Annu Rev Biochem 2018;87:897–919.
[7] Gonzalez A, Cordomi A, Caltabiano G, Campillo M, Pardo L. Impact of helix irregularities on sequence alignment and homology modelling of G protein-coupled receptors. ChemBioChem 2012;13:1393–9.
[8] Ciruela F, Canela L, Burgueno J, Sorguera A, Cabello N, Canela EI, et al. Hepatopancreatic membrane receptors and cytoskeletal/scaffoldling proteins: focus on adenosine, dopamine, and metabolotropic glutamate receptor function. J Mol Neurosci 2005;29:277–92.
[9] Keuperleber S, Gsandtner I, Freissmuth M. From cradle to twilight: the carboxyl terminus directs the fate of the A(2A)/adenosine receptor. Biochim Biophys Acta 2011;1808:1350–7.
[10] Klinger M, Kuhn M, Just H, Stefan E, Palmer T, Freissmuth M, et al. Removal of the carboxy terminus of the A2A-adenosine receptor blunts constitutive activity: differential effect on cAMP accumulation and MAP kinase stimulation. Naunyn Schmiedebergs Arch Pharmacol 2002;366:287–98.
[11] Navarro G, Ferre S, Cordomi A, Moreno E, Mallol J, Casado V, et al. Interactions between intracellular domains as key determinants of the quaternary structure and function of receptor heteromers. J Biol Chem 2010;285:27346–59.
[12] Kofalvi A, Moreno E, Cordomi A, Cai NS, Fernandez-Duenas V, Ferreira SG, et al. Control of glutamate release by complexes of adenosine and cannabinoid receptors. BMC Biol 2020;18:9.
[13] Navarro G, Cordomi A, Brugarolas M, Moreno E, Aguinaoa D, Perez-Beito L, et al. Cross-communication between Gi and Gq in a G-protein-coupled receptor heteroreceptor guided by a receptor C-terminal domain. BMC Biol 2018;16:24.
[14] de Lera Ruiz M, Lim YH, Zheng J. Adenosine A2A receptor as a drug discovery target. J Med Chem 2014;57:3623–50.
[15] Gutierrez-de-Teran H, Sallander J, Sotelo E. Structure-based rational design of adenosine receptor ligands. Curr Top Med Chem 2017;17:40–58.
[16] Domenici MR, Ferrafaglia A, Martire A, Chiodi V, Poppani R, Tebano MT, et al. Adenosine A2A receptor as potential therapeutic target in neuropsychiatric disorders. Pharmacol Res 2019;147:104338.
[17] Dungo R, Deeks ED. Istradefylline: first global approval. Drugs 2013;73:875–82.
[18] Wisler JW, Rockman HA, Lefkowitz RJ. Biased G protein-coupled receptor signaling: changing the paradigm of drug discovery. Circulation 2018;137:2315–7.
[19] Valant C, May LT, Auricelo L, Chuc TH, White PJ, Balta JS, et al. Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. PNAS 2014;111:4614–9.
[20] Smith JS, Lefkowitz RJ, Rajagopal S. Biased signalling: from simple switches to allosteric microprocessors. Nat Rev Drug Discov 2018;17:243–60.
[21] Burgueno J, Blake DJ, Benson MA, Tinsley CL, Espata CT, Canela EI, et al. The adenosine A2A receptor interacts with the actin-binding protein alpha-actinin. J Biol Chem 2003;278:37549–52.
[22] Medrano M, Aguinaoa I, Reyes-Resina I, Canela EI, Mallol J, Navarro G, et al. Orexin A/hypocretin modulates leptin receptor-mediated signaling by allosteric modulations mediated by the ghrelin GHS-R1A receptor in hypothalamic neurons. Mol Neurobiol 2018;55:4718–30.
